CFA
SGMO

Camarda Financial Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Camarda Financial Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-800
Closed -$6K – 213
2013
Q2 		$6K Buy
+800
New +$6.98K 0.01% 189

Other funds holding SGMO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Camarda Financial Advisors's SGMO Position: Q3 2013 in Review

Camarda Financial Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2013, closing a stake of 800 shares — an estimated $6K sold.

Camarda Financial Advisors first reported a position in SGMO in Q2 2013 and held it in 1 quarter. The position peaked at $6K in Q2 2013. 111 funds tracked by Wall St. Rank hold SGMO as of Q3 2013.

  • Camarda Financial Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2013 after selling out during the quarter.
  • Camarda Financial Advisors sold 800 SANGAMO THERAPEUTICS INC shares in Q3 2013, an estimated $6K.
  • Camarda Financial Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 1 quarter.
  • Camarda Financial Advisors's SANGAMO THERAPEUTICS INC position peaked at $6K in Q2 2013.
  • 111 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2013.

Based on Camarda Financial Advisors's 13F filing for Q3 2013, filed 6 Nov 2013.